RT Journal Article
T1 Antimicrobial Susceptibility and Characterization of Resistance Mechanisms of Corynebacteriumurealyticum Clinical Isolates.
A1 Chapartegui-González, Itziar
A1 Fernández-Martínez, Marta
A1 Rodríguez-Fernández, Ana
A1 Rocha, Danilo J P
A1 Aguiar, Eric R G R
A1 Pacheco, Luis G C
A1 Ramos-Vivas, José
A1 Calvo, Jorge
A1 Martínez-Martínez, Luis
A1 Navas, Jesús
K1 Corynebacterium urealyticum
K1 antimicrobials
K1 coryneform
K1 multidrug resistance
K1 whole genome sequencing
AB Corynebacterium urealyticum is a non-diphtherial urease-producing clinically relevant corynebacterial, most frequently involved in urinary tract infections. Most of the C. urealyticum clinical isolates are frequently resistant to several antibiotics. We investigated the susceptibility of 40 C. urealyticum isolated in our institution during the period 2005-2017 to eight compounds representative of the main clinically relevant classes of antimicrobial agents. Antimicrobial susceptibility was determined by the Epsilometer test. Resistance genes were searched by PCR. All strains were susceptible to vancomycin whereas linezolid and rifampicin also showed good activity (MICs90 = 1 and 0.4 mg/L, respectively). Almost all isolates (39/40, 97.5%) were multidrug resistant. The highest resistance rate was observed for ampicillin (100%), followed by erythromycin (95%) and levofloxacin (95%). Ampicillin resistance was associated with the presence of the blaA gene, encoding a class A β-lactamase. The two rifampicin-resistant strains showed point mutations driving amino acid replacements in conserved residues of RNA polymerase subunit β (RpoB). Tetracycline resistance was due to an efflux-mediated mechanism. Thirty-nine PFGE patterns were identified among the 40 C. urealyticum, indicating that they were not clonally related, but producing sporadic infections. These findings raise the need of maintaining surveillance strategies among this multidrug resistant pathogen.
SN 2079-6382
YR 2020
FD 2020-07-13
LK https://hdl.handle.net/10668/28030
UL https://hdl.handle.net/10668/28030
LA en
DS RISalud
RD Apr 7, 2025